LY3305677

Mazdutide is a once-weekly injectable peptide that activates two receptors at once: GLP-1, the gut hormone that signals satiety, and glucagon, the hormone that nudges the body to burn more energy. Eli Lilly developed it as LY3305677 and licensed Greater China rights to Innovent Biologics, where it carries the code IBI362. The US program sits at Phase 2 under a master protocol (NCT06143956) testing multiple doses in adults with obesity [1]. China is well ahead: Innovent has reported positive Phase 3 weight-loss and type 2 diabetes outcomes in Chinese populations [2][3] and NMPA approved mazdutide for chronic weight management (the first GLP-1/glucagon dual agonist approved for obesity anywhere) and subsequently for T2D glycemic control on 2025-09-19 [12]. The commercial question is what mazdutide adds in Western markets where Lilly already sells tirzepatide (Mounjaro/Zepbound) at a roughly $16.5B annualized run-rate as of late 2025 [4] and is finishing Phase 3 on retatrutide. The signal worth tracking is the head-to-head Phase 3 against semaglutide in fatty liver disease (NCT06884293), where glucagon agonism could show a liver-specific edge [5] - though Boehringer's survodutide, another GLP-1/glucagon dual agonist with FDA Breakthrough Therapy designation in MASH, has Phase 3 LIVERAGE readouts expected in late 2026 and may set the bar first [11].

Novel compound from Lilly's incretin platform, partnered to Innovent for Greater China where it trades as IBI362. The US program is Phase 2: NCT06143956 (LY900038) is a master protocol enrolling ~1,481 adults with obesity or overweight across multiple intervention-specific appendices [1]. A predecessor placebo-controlled Phase 2 (NCT06124807, n=179) completed earlier with body weight at week 32 as the primary endpoint [6]. No FDA breakthrough therapy, fast track, orphan, or accelerated approval designations are on record for mazdutide (notably, competitor survodutide does hold FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate/advanced fibrosis [11]). China is the leading geography: Phase 3 results in T2D versus placebo and versus dulaglutide were published in Nature in 2026 [2][3], a Phase 2 obesity trial at 9 mg reported in Med [7], and Innovent has secured NMPA approval for chronic weight management (first-in-world for the GLP-1/glucagon class) followed by T2D glycemic control approval on 2025-09-19 [12]. Commercial launch metrics and pricing detail from Innovent have not been publicly disclosed in detail as of 2026-06-02. Additional Phase 3 work is ongoing - IBI362 versus semaglutide in metabolic dysfunction-associated fatty liver disease (NCT06884293, n=479, active not recruiting) [5] and IBI362 in hypertensive overweight/obese patients (NCT07469800, n=336, recruiting) [8]. US Phase 3 timing for obesity has not been disclosed in Lilly's 2025 10-K beyond pipeline mention [9].

GLP-1 is the gut hormone your body releases when you eat. It tells the pancreas to release insulin and tells the brain that you're full. Glucagon is the opposite hormone for blood sugar - it tells the liver to release glucose - but it also raises resting energy expenditure, meaning you burn more calories at rest. Hitting both receptors with one drug means you eat less AND burn more. That is the theoretical edge over GLP-1-only drugs like semaglutide. The catch is that glucagon agonism can raise blood sugar if mis-tuned, so the GLP-1-to-glucagon activity ratio has to be calibrated carefully. Mazdutide leans GLP-1-heavy, which preserves glycemic control while still recruiting glucagon's energy-burn effect. The dual-agonist concept is now well-validated: Lilly's tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/glucagon) both outperform semaglutide on weight loss in head-to-head and cross-trial data. Mazdutide is the GLP-1/glucagon branch of the same family tree (survodutide is the other GLP-1/glucagon dual agonist in late development). GLP1R has Open Targets evidence scores of 0.77 for T2D and 0.72 for obesity - both are validated targets, not biological gambles. Glucagon receptor agonism is the newer mechanism and the source of most of the unknowns, but it is not first-in-class: cotadutide (AstraZeneca, discontinued) and survodutide (Boehringer/Zealand, Phase 3) hit the same receptor pair.

NCT06143956 is the US Phase 2 master protocol (LY900038), a basket design with multiple intervention-specific appendices (ISAs) that lets Lilly evaluate different doses and regimens under one umbrella [1]. The listed primary endpoint is allocation across ISAs, which is a placeholder for the master protocol structure; each ISA has its own efficacy endpoint, typically percent change in body weight at week 32 or 52. Population is adults with BMI ≥30 or ≥27 with weight-related comorbidities. Comparator is placebo within each ISA. Total enrollment target is ~1,481 and the trial is recruiting. The predecessor Phase 2 (NCT06124807, n=179) was a cleaner placebo-controlled readout with body weight at week 32 as the primary [6]. The most informative active trial is NCT06884293, a Chinese Phase 3 head-to-head versus semaglutide in fatty liver disease patients (n=479, active not recruiting), with percentage body weight change as the primary [5]. Clinical-readers note: MAFLD is the broad umbrella of liver fat accumulation driven by metabolic disease; MASH is the more severe inflamed/fibrotic subset and the FDA-recognized indication for drug approval in liver disease. NCT06884293 is labeled as MAFLD with body weight as the primary endpoint - it is not a MASH histology trial, so any leap to MASH commercial positioning will require additional dedicated histology-endpoint trials. NCT07469800 (Phase 3, hypertensive obesity, n=336) tests blood pressure as a primary, looking for a cardiovascular dimension beyond weight [8]. FDA path consideration: dedicated cardiovascular outcomes trial (CVOT) data may be required before or alongside US approval given glucagon agonism's known effect on heart rate; whether Lilly will run a dedicated CVOT or pursue an expedited pathway based on surrogate endpoints has not been disclosed and adds uncertainty to US Phase 3 timeline and cost.

Our model estimates a 22% chance this drug is eventually approved. That figure starts from the historical approval rate for Phase 2 drugs in this area, around 35%, then adjusts based on ten facts about the trial and sponsor. The estimate gets a boost from larger-than-typical enrollment and the sponsor's strong approval track record, but is pulled down by few secondary endpoints and weak earlier-phase results. The remaining factors fell close to average, so they left the number roughly where the base rate set it.

Four concrete failure modes. (1) Efficacy ceiling. Semaglutide delivers ~15% weight loss and tirzepatide ~22% at max dose in Western Phase 3 trials (STEP 1, SURMOUNT-1); retatrutide ~24% in Phase 2. Chinese Phase 2 data on mazdutide at 9 mg showed mid-teens percent weight loss [7] and the Azam meta-analysis pooled estimate is ~12.4% [10] - comparable to semaglutide peak-dose benchmarks, but direct comparison is confounded by population (lower baseline BMI in Chinese cohorts), dose, and trial design. Western Phase 2 dose-ranging data from NCT06143956 is needed before the efficacy gap to tirzepatide can be reliably assessed. (2) Glucagon-mediated tolerability and CVOT exposure. Glucagon agonism can raise heart rate, elevate liver enzymes, and degrade glucose control if the receptor balance drifts. AstraZeneca's cotadutide program was discontinued partly for tolerability and efficacy reasons. Chinese trials reported acceptable safety [2][3], but the FDA will look hard at cardiovascular and hepatic signals at the doses needed for Western body weights and may require a dedicated CVOT before approval - a multi-year, multi-hundred-million-dollar requirement that would extend the US timeline. (3) Direct competition in liver disease. Survodutide (BI 456906, Boehringer/Zealand) is also a GLP-1/glucagon dual agonist, holds FDA Breakthrough Therapy designation for non-cirrhotic MASH, and has Phase 3 LIVERAGE and LIVERAGE-Cirrhosis MASH readouts expected later in 2026 [11]. If survodutide reads out first and positively, it sets the efficacy bar mazdutide must clear and competes for the same liver-disease positioning. (4) Commercial cannibalization. Even if approved in the US, mazdutide enters a Lilly-owned market: Mounjaro/Zepbound (tirzepatide) at ~$16.5B run-rate [4] and retatrutide approaching approval. Lilly may position mazdutide for second-line use, specific comorbidities (MAFLD, hypertension), or geographies rather than first-line obesity, which caps revenue potential.

Worth watching, not the headline. Mazdutide is Lilly hedging across the incretin combinatorial space: GLP-1 alone (dulaglutide), GLP-1/GIP (tirzepatide), GLP-1/glucagon (mazdutide), GLP-1/GIP/glucagon (retatrutide). The portfolio is the story. The specific signal to track is NCT06884293, the head-to-head Phase 3 against semaglutide in MAFLD patients with body weight as the primary endpoint. Glucagon agonism increases hepatic fat oxidation directly, which is a different mechanism from semaglutide's weight-loss-driven liver benefit. If mazdutide beats semaglutide on weight (and ideally liver fat by imaging in a substudy) by a clinically meaningful margin, MASH becomes a plausible commercial entry point in the West - though MASH approval will require dedicated histology-endpoint trials beyond NCT06884293, and Boehringer's survodutide (FDA Breakthrough Therapy in MASH, Phase 3 LIVERAGE readout expected late 2026 [11]) is the direct competitor for that positioning. Whoever reads out first and positively sets the bar. The NCT06884293 readout is expected in 2026-2027 based on active-not-recruiting status [5]. The US Phase 2 master protocol (NCT06143956) is dose-finding for Western populations and informative for FDA strategy but less interesting as a market signal. The China commercial trajectory - NMPA approval already in hand for obesity (first-in-world for the class) and T2D (2025-09-19) [12] - is a clean de-risking signal for the dual-agonist franchise, but Innovent has not publicly disclosed launch metrics or pricing, so the proof-of-concept dollar figures are not yet quantifiable. Watch Innovent quarterly reports and Lilly earnings for the first concrete China revenue data and any US Phase 3 initiation.